Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics, based in South Plainfield, N.J., announced that Mary Frances Harmon, its Senior Vice President of Corporate and Patient Relations, has been named one of the most inspiring leaders in life sciences by PharmaVOICE magazine. Harmon is recognized for her dedication to improving patient lives and her work in establishing relationships with patients and advocacy groups. With over 30 years in the pharmaceutical industry, she has initiated programs like the STRIVE awards to support Duchenne muscular dystrophy patients. PTC continues to emphasize its commitment to patient-focused initiatives.
PTC Therapeutics (PTCT) reported Q2 2020 revenues of $75.2 million, down from $85.5 million YoY, driven by a decrease in Translarna sales.
However, Emflaza experienced a growth of over 30% YoY. R&D expenses surged to $176.5 million, including one-time charges of $53.6 million from Censa Pharmaceuticals acquisition.
Despite a net loss of $181.4 million, PTC holds over $1 billion in cash, positioning it well for future developments.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call on August 5, 2020, at 4:30 p.m. ET to report its Q2 2020 financial results and business outlook. Investors can join the call by dialing (877) 303-9216 domestically or (973) 935-8152 internationally and using passcode 5897698. A live webcast will also be available on the company's website. PTC focuses on developing and commercializing innovative medicines for rare disorders and aims to provide access to transformative treatments for patients with unmet medical needs.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the European Medicines Agency's CHMP recommended removing the statement regarding the lack of efficacy in non-ambulatory patients from the SmPC for Translarna™ (ataluren). This change allows healthcare providers to make treatment decisions based on clinical judgment for non-ambulatory patients. The recommendation may facilitate reimbursement for these patients. Translarna, which treats Duchenne muscular dystrophy caused by nonsense mutations, has demonstrated potential benefits in slowing disease progression and preserving lung function.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has received FDA authorization to initiate a Phase 2/3 clinical trial for PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, aimed at treating COVID-19. The trial, starting imminently in the U.S. and expanding globally, will evaluate the drug's efficacy in reducing SARS-CoV-2 replication and managing inflammation associated with COVID-19. The study will involve around 340 patients, measuring clinical efficacy against a placebo through respiratory improvement. PTC299 is also under investigation for oncology applications, having shown promising results in prior trials.